30 September 2005

A press release by Schering AG, manufacturer of the Multiple Sclerosis drug Betaseron, reports drug trial results showing a 50% reduction in risk of developing clinically definite MS after a single attack suggestive of MS, supporting early treatment of people at risk for MS.

Previously, Betaseron had been shown to reduce the number (and severity?) of relapses in relapsing-remitting MS, and to slow progression of disability in secondary-progressive MS.

Labelling changes will be sought from "regulatory authorities" as a result of the study.